EXHIBIT A

| | Page 1 |
|----|--|
| 1 | IN THE UNITED STATES DISTRICT COURT |
| | FOR THE DISTRICT OF MASSACHUSETTS |
| 2 | |
| 3 | |
| 4 | IN RE: |
| |) CA No. 04-10981-PBS |
| 5 | NEURONTIN MARKETING, SALES PRACTICES,) Pages 1 - 107 |
| | AND PRODUCTS LIABILITY LITIGATION) |
| 6 | |
| 7 | |
| 8 | |
| 9 | FINAL PRETRIAL CONFERENCE - DAY ONE |
| 10 | BEFORE THE HONORABLE PATTI B. SARIS |
| | UNITED STATES DISTRICT JUDGE |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| | United States District Court |
| 15 | 1 Courthouse Way, Courtroom 19 |
| | Boston, Massachusetts |
| 16 | July 20, 2009, 9:15 a.m. |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| | LEE A. MARZILLI |
| 23 | OFFICIAL COURT REPORTER |
| | United States District Court |
| 24 | 1 Courthouse Way, Room 7200 |
| | Boston, MA 02210 |
| 25 | (617)345-6787 |
| | |

Page 2 Page 4 APPEARANCES: 1 Chaffin. 2 2 MR. SOH: Ken Soh for the plaintiffs, your Honor. FOR THE PLAINTIFFS: 3 MS. HEGAR: Dara Hegar, Lanier Law Firm. 3 ANDREW G. FINKELSTEIN, ESQ., KENNETH B. FROMSON, ESQ., THE COURT: Are you all going to be here next 4 and KEITH L. ALTMAN, ESQ., Finkelstein & Partners, LLP, 5 week? That's huge. All right. 1279 Route 300, P.O. Box 1111, Newburgh, New York, 12550. 6 So we start with basics. Next Monday we will be KENNETH S. SOH, ESQ. and DARA GRISBEE HEGAR, ESQ., 7 impaneling a jury. The one thing I probably didn't tell you The Lanier Law Firm, 126 East 56th Street, 6th Floor, 6 8 is, to make matters more complicated, I am sitting with the New York, New York, 10022. First Circuit by designation for four cases in the morning. FOR THE DEFENDANTS: 10 And so I'm not sure a hundred percent when that's going to DAVID B. CHAFFIN, ESO., White and Williams, LLP, finish, and what I'm thinking of doing is asking the jury 11 100 Summer Street, Suite 2707, Boston, Massachusetts, 02110. 10 12 clerk to bring in a group of people for a 2:00 o'clock KATHRINE ARMSTRONG, ESQ. and MARK S. CHEFFO, ESQ., 13 impanelment. That might be just as easy for you all, it's a Skadden, Arps, Slate, Meagher & Flom, LLP, Four Times 11 14 Monday morning, rather than just having all the jurors Square, New York, New York, 10036. 12 15 sitting downstairs stewing and annoyed until I'm done with WILLIAM S. OHLEMEYER, ESQ., Boies, Schiller & Flexner, 16 the First Circuit. So they will have eaten lunch. We will 13 575 Lexington Avenue, 7th Floor, New York, New York, 10022. 17 impanel. I do not expect that it should take longer than 14 15 18 three hours, but what it essentially does mean is that you 16 19 need to block off your afternoon. So that's for starters. 17 18 20 The second thing is, I was thinking -- I saw 19 21 somewhere on the list -- you were possibly on the same page 20 22 with me -- of ten jurors. Given the fact that we were going 21 22 23 into three weeks, I could possibly lose some. So if that's 23 24 so, it's essentially five peremptories a side. The way I do 24 things is, there are no back challenges. So I'll first ask 25 Page 3 Page 5 PROCEEDINGS 1

7

2 THE CLERK: In Re: Neurontin Marketing, Sales 3 Practices, and Products Liability Litigation, Civil Action

No. 04-10981, will now be heard before this Court. Will

5 counsel please identify themselves for the record.

4

7

21

6 MR. FINKELSTEIN: Good morning, your Honor. Andrew Finkelstein, Finkelstein & Partners, on behalf of 8 Dr. Egilman.

9 MR. FROMSON: Good morning, your Honor. Kenneth 10 Fromson, Finkelstein & Partners.

MR. ALTMAN: Good morning, your Honor. Keith 11 12 Altman, Finkelstein & Partners.

13 MS. ARMSTRONG: Good morning, your Honor.

14 Katherine Armstrong from Skadden Arps.

15 MR. CHEFFO: Good morning, your Honor. Mark 16 Cheffo from Skadden Arps.

MR. OHLEMEYER: Good morning, Judge. Bill 17 18 Ohlemeyer, Boise Schiller.

19 MR. GOODELL: Good morning, your Honor. Charlie 20 Goodell, Goodell DeVries.

THE COURT: You're representing?

22 MR. GOODELL: Pfizer.

23 MR. CHEFFO: Good morning, your Honor. Rick 24 Barnes for Pfizer as well, Goodell DeVries in Baltimore.

25

MR. CHAFFIN: Good morning, your Honor. David

plaintiffs to exercise their challenges, then defendants. 1

2 We'll strike people. We'll put people in the box for those 3 empty seats. The next time around defendants go first. The

4 defendants will challenge, then plaintiffs will challenge,

5 and so on until you use up your peremptories. But I don't 6

let you go back. In other words, if you've already passed on a juror, you're stuck with the juror.

8 Because it's vacation time, I wanted to play out a 9 procedure for you. One of the things that annoys me no end, 10 but there seems to be no clear solution, is when I get my 11 pool of 50 jurors and half of them say, "I don't want to

12 serve because I'm going on vacation." I was thinking of

13 giving the jury clerk essentially a questionnaire to be

14 filled in under oath so that we don't bring up jurors who 15

have already prepaid vacation plans. I'm thinking about that. The problem is, it's too easy an out for people. 16

17 It's a three-week trial which would be hard for people

18 anyway. So another way to do it is to simply ask for more

19 people, and then just have everybody who's got a vacation

20 plan come up and swear to me, and then just let them go.

21 Judge Gertner tried a technique which I really liked a lot, 22 which she had them fill it in under oath, a questionnaire

23 downstairs, and basically gave the -- I think brought up the

24 questionnaires, I okayed them so it was a judge's blessing,

25 and then we either sent them to another court or we Page 54 Page 56

2005, if the company received a report of completed suicide, 1 they sent it to the FDA saying that "This is an unlabeled event, it's not in our label." But yet all of their experts want to get up in front of the jury and say, "But it really

5 was in the label." The company --

6

7

8

9

10

11

12

13

14

15

20

21

22

23

24

1

14

16

17

18

19

20

21

THE COURT: It does say that, "suicidal." It says "suicidal."

MR. ALTMAN: But from a regulatory perspective, the company considered a completed suicide report to be unlabeled. Their own records, there's a statement by the company that suicide is an unlabeled event.

THE COURT: Can I say something? This is one of these things where maybe you all put a lot of -- but when I hear "suicidal" and when a jury hears it, they're going to think that it means anything -- actually, I would have thought it meant trying to commit suicide or committing it.

17 Now, if it doesn't, you've got to be careful how you word 18

this, but they're allowed to put in the package insert. 19 MR. ALTMAN: But if that were true, your Honor,

then why did they tell the FDA it's not in the label? THE COURT: I don't know. Ask them that question.

MR. FROMSON: Your Honor, we're not saying they can't utilize the package insert. They just can't say "We warn for suicide" as the term is used in the industry. That

25 would be untrue. 1 MR. BARNES: We're not going to argue that we were 2 legally prohibited from putting in a CBE. We do want to 3 talk about, and it goes with what Katherine was saying, we do want to talk about the whole context of what we did and 4 5 why we did it and why we did not feel it was appropriate. 6 We're not making a legal argument we couldn't have, but we 7 want to explain the context. 8

THE COURT: All right, that's got to be part of your -- just as they're putting in all this marketing stuff, you've got to be able to put in what the corporation was thinking about.

MR. BARNES: Absolutely. Okay, thank you.

13 THE COURT: Fair enough. 14

Plaintiffs' motion in limine to preclude the testimony of all the defendants' expert witnesses other than Dr. Gibbons concerning the FDA alert and related FDA subjects. I don't know --

MR. CHEFFO: I mean, I'm not sure I really understand. I mean, I think that they say that because he was somehow qualified, that no one else can refer to it? I mean --

22 THE COURT: Well, let me put it this way: This is 23 denied, but to the extent it starts getting cumulative, you 24 don't have that much time. I mean, time is a fabulous 25

discipline.

9

10

11

12

15

16 17

18

19

20

21

7

8

Page 55

THE COURT: Just say "suicidal."

2 MS. ARMSTRONG: Your Honor, just to be clear, we 3 are not going to argue that the label in 2005 or in 2004 contained a warning for suicide. They are confusing 4 5 different components of the label to the warning section and 6 an adverse events section. Our experts are going to talk 7 about what was contained in the adverse events section,

8 which does include references to suicidal and suicidal 9 gesture; and they're going to explain why that was appropriate in light of what was known at the time, what it 10 would mean to a reasonable physician. That's going to be 11

12 the type of testimony we present. 13

THE COURT: All right, fine.

Motion in limine to preclude any testimony or discussion by defendants that they could not have amended the Neurontin label or issued strengthened warnings without prior FDA approval. That's just a legal argument.

MR. FROMSON: I don't really think there's a disagreement. After having read their papers, they didn't deny that there were federal regulations --

THE COURT: So allowed.

22 MR. FROMSON: Thank you, Judge.

23 THE COURT: Allowed.

24 MR. BARNES: Your Honor, if I may?

25 THE COURT: Yes, yes. 1 MR. CHEFFO: We don't disagree with that at all, 2 your Honor.

3 MR. FROMSON: Judge, very briefly -- and I 4 understand your order clearly -- they went out and got 5 Gibbons for the FDA alert because he was the only one in the 6 world uniquely qualified to do it.

THE COURT: You know, come on, that's just all litigation posturing.

9 MR. FROMSON: Well, that's the way to posture to 10 the Court in order to get the Court to allow him to do the rebuttal. 11

12 THE COURT: He's a statistician, just like 13 Greenland is. It's very hard stuff. So, I mean, he's the 14 only guy who's qualified, as far as I know, on statistics, 15 but there may be other aspects about the regulatory system 16 that other people can comment on.

17 MR. FROMSON: So then I think we're in agreement 18 that all the other experts couldn't come in and give

19 statistical opinion. 20

THE COURT: They can't give a statistical analysis unless they're qualified.

22 MR. FROMSON: Thank you, Judge.

23 THE COURT: I mean, I don't think any --

24 MR. CHEFFO: But that's how this motion was. I don't think we're going to have nonstatisticians talking,

Page 57

21